Isolated ACTH deficiency induced by cancer immunotherapy: a systematic review

P Iglesias, JC Sánchez, JJ Díez - Pituitary, 2021 - Springer
Immunotherapy with immune checkpoint inhibitor (ICI) monoclonal antibodies has shown to
be an effective therapeutic alternative in several malignant tumors. However, adverse effects …

[HTML][HTML] Safety and tolerability of immune checkpoint inhibitors (PD-1 and PD-L1) in cancer

I Baraibar, I Melero, M Ponz-Sarvise, E Castanon - Drug safety, 2019 - Springer
Immunotherapy has emerged in recent years and has revolutionized the treatment of cancer.
Immune checkpoint inhibitors, including anti-cytotoxic T lymphocyte antigen-4 (CTLA-4), anti …

Hypophysitis secondary to nivolumab and pembrolizumab is a clinical entity distinct from ipilimumab-associated hypophysitis

A Faje, K Reynolds, L Zubiri, D Lawrence… - European journal of …, 2019 - academic.oup.com
Objective Little has been published describing hypophysitis after nivolumab or
pembrolizumab treatment. We aimed to (i) assess the risk of hypophysitis following …

[HTML][HTML] Anti-pituitary antibodies and susceptible human leukocyte antigen alleles as predictive biomarkers for pituitary dysfunction induced by immune checkpoint …

T Kobayashi, S Iwama, D Sugiyama… - … for immunotherapy of …, 2021 - ncbi.nlm.nih.gov
Background Pituitary dysfunction is a life-threatening immune-related adverse event (irAE)
induced by immune checkpoint inhibitors (ICIs). To date, it is not possible to identify patients …

Immune checkpoint inhibitors in non-small cell lung cancer: A bird's eye view

H Memon, BM Patel - Life sciences, 2019 - Elsevier
Lung cancer is the leading cause of cancer-related mortality worldwide. Treatment with
immunotherapy has made a significant impact on the outcomes for those patients suffering …

[HTML][HTML] Isolated adrenocorticotropic hormone deficiency and thyroiditis associated with nivolumab therapy in a patient with advanced lung adenocarcinoma: a case …

N Ohara, M Kobayashi, K Ohashi, R Ito, Y Ikeda… - Journal of medical case …, 2019 - Springer
Introduction Immune checkpoint inhibitors are a promising class of anticancer drugs. The
clinical benefits afforded by immune checkpoint inhibitors can be accompanied by immune …

[HTML][HTML] Eosinophil counts can be a predictive marker of immune checkpoint inhibitor-induced secondary adrenal insufficiency: A retrospective cohort study

S Takayasu, S Mizushiri, Y Watanuki, S Yamagata… - Scientific Reports, 2022 - nature.com
Immune checkpoint inhibitors (ICIs) treatment can result in endocrine immune-related
adverse events (irAEs), including pituitary dysfunction. Quick diagnosis of secondary …

[HTML][HTML] Isolated adrenocorticotropic hormone deficiency associated with sintilimab therapy in a patient with advanced lung adenocarcinoma: a case report and …

SH Lin, A Zhang, LZ Li, LC Zhao, LX Wu… - BMC Endocrine …, 2022 - Springer
Background Several immune checkpoint inhibitors have been implemented for cancer
treatment which have shown some degree of antitumor effcacy, while immune-related …

[PDF][PDF] Association between peripheral eosinophils and clinical outcomes in patients with non–small cell lung cancer treated with immune checkpoint inhibitors

S Okauchi, T Shiozawa, K Miyazaki… - Polish Archives of …, 2021 - tsukuba.repo.nii.ac.jp
IntroductIon Programmed cell death ligand 1 is considered a predictor of the therapeutic
effect of immune checkpoint inhibitors (ICPIs), but a more simple and useful predictor is …

Immune checkpoint inhibitor–associated hypercalcaemia

H Izzedine, T Chazal, R Wanchoo… - Nephrology Dialysis …, 2022 - academic.oup.com
Immune checkpoint inhibitors (CPIs) have recently become a cornerstone for the treatment
of different advanced cancers. These drugs have the ability to reactivate the immune system …